Patents by Inventor Matthew Baggott

Matthew Baggott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
    Publication number: 20240083864
    Abstract: Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
    Type: Application
    Filed: September 22, 2023
    Publication date: March 14, 2024
    Inventor: Matthew Baggott
  • Advantageous benzofuran compositions for mental disorders or enhancement
    Patent number: 11767305
    Abstract: Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: September 26, 2023
    Assignee: Tactogen Inc
    Inventor: Matthew Baggott
  • ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
    Publication number: 20230257347
    Abstract: Pharmaceutically active advantageous tryptamine compounds and their pharmaceutically acceptable salts, salt mixtures and pharmaceutically acceptable compositions are disclosed for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy, and generally for modulating central nervous system activity.
    Type: Application
    Filed: March 20, 2023
    Publication date: August 17, 2023
    Applicant: Tactogen Inc
    Inventor: Matthew Baggott
  • 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT
    Publication number: 20230183199
    Abstract: The present invention discloses 2-aminoindane Formulas I and II and their pharmaceutically acceptable salts, compositions and methods of use to modulate central nervous system activity, and to treat central nervous system disorders, such as post-traumatic stress, depression, anxiety, and adjustment disorders. In certain embodiments, the compounds of the present invention can be used for entactogenic therapy in counseling sessions, as needed periodically or consistently as necessary or desired.
    Type: Application
    Filed: February 6, 2023
    Publication date: June 15, 2023
    Applicant: Tactogen Inc.
    Inventor: Matthew Baggott
  • ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
    Publication number: 20230159487
    Abstract: Pharmaceutically active benzothiophene compounds and their pharmaceutically acceptable salts and salt mixtures and pharmaceutically acceptable compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy, and generally for modulating central nervous system activity.
    Type: Application
    Filed: January 5, 2023
    Publication date: May 25, 2023
    Applicant: TACTOGEN INC
    Inventor: Matthew Baggott
  • ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
    Publication number: 20230150963
    Abstract: Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
    Type: Application
    Filed: December 8, 2022
    Publication date: May 18, 2023
    Applicant: Tactogen Inc.
    Inventor: Matthew Baggott